Ogurtsova K,da Rocha Fernandes JD,Huang Y,Linnenkamp U,Guariguata L,Cho NH .2017 .IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract, 03 : 40-50.
Glovaci D,Fan W,Wong ND .2019 .. Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Curr Cardiol Rep, 10(4) : 21.
Dal Canto E,Ceriello A,Rydén L,Ferrini M,Hansen TB,Schnell O .2019 .Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol, 10(2) : 25-32.
Luo Y,Lu K,Liu G,Wang J,Laurent I,Zhou X. .2018 .The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Drug Investig, 38(12) : 1089-108.
Morrish NJ,Wang SL,Stevens LK,Fuller JH,Keen H. Mortality .2001 .and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia, 44(S2) : S14-21.
Fei Y,Tsoi MF,Kumana CR,Cheung TT,Cheung BMY .2017 .Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. Int J Cardiol, 12 : 291-6.
Thornberry NA,Gallwitz B. Mechanism .2009 .of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab, 03(4) : 479-86.
Gadsby R .2007 .New treatments for type 2 diabetes--the DPP4 inhibitors. Prim Care Diabetes, 10(4) : 209-11.
Lambeir AM,Scharpé S,De Meester I. .2008 .DPP4 inhibitors for diabetes-. Biochem Pharmacol, 07(12) : 1637-43.
Xia C,Goud A,D'Souza J,Dahagam C,Rao X,Rajagopalan S .2017 .DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Fail Rev, 10(3) : 299-304.
Zheng SL,Roddick AJ,Aghar-Jaffar R,Shun-Shin MJ,Francis D,Oliver N .2018 .Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. JAMA, 10(15) : 1580.
Papagianni M,Tziomalos K. .2015 .Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. , 19(3) : 195-9.
Scheen AJ .2018 .Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circ Res, 122(10) : 1439-59.
Fei Y,Tsoi MF,Cheung BMY .2019 .Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol, 10(1) : 1-3.
Kim YG,Yoon D,Park S,Han SJ,Kim DJ,Lee KW .2017 .Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus. Circ Heart Fail, 10(9) : e003957.
Alfayez OM,Al Yami MS,Alshibani M,Fallatah SB,Al Khushaym NM,Alsheikh R .2019 .Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Prim Care Diabetes, 01(3) : 204-11.
Thein D,Christiansen MN,Mogensen UM,Bundgaard JS,Rørth R,Madelaire C .2020 .Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovasc Diabetol, 19(1) : 1-11.
Dawwas GK,Smith SM,Park H .2018 .Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. Cardiovasc Diabetol, 10(1) : 1-9.
Liu H,Guo L,Xing J,Li P,Sang H,Hu X .2020 .The protective role of DPP4 inhibitors in atherosclerosis. Eur J Pharmacol, 10 : 173037.
Lee S,Lee SA,Choi B,Kim YJ,Oh SJ,Choi HM .2020 .Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis. Heart, 106(23) : 1824-31.
Nishida S,Matsumura T,Senokuchi T,Murakami-Nishida S,Ishii N,Morita Y .2020 .Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions. Biochem Biophys Res Commun, 01(1) : 8-15.